上海海顺新型药用包装材料股份有限公司 关于募集资金半年度存放与使用情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求（2022 年修订）》（证监会 公告〔2022〕15 号）和深圳证券交易所印发的《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》（深证上 〔2022〕14 号）的规定，将本公司募集资金 2023 年半年度存放与使 用情况专项说明如下。 一、募集资金基本情况 (一) 向特定对象发行股票 1、实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2021〕2377 号文核准， 并经深圳证券交易所同意，本公司由主承销商中信证券股份有限公司 采用询价方式，向特定对象发行人民币普通股（A 股）股票 37,181,705 股，发行价为每股人民币 16.18 元，共计募集资金 601,599,986.90 元，坐扣承销和保荐费用 3,309,433.90 元（不含税）以及税金 198,566.03 元后的募集资金为 598,091,986.97 元，已由主承销商中 信证券股份有限公司于 2021 年 9 月 ...

| 证券代码：300501 | 证券简称：海顺新材 公告编号：2023-059 | | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | 上海海顺新型药用包装材料股份有限公司 关于举办2023年半年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2023年8月25日在巨潮资讯网（http://www.cninfo.com.cn）披露 了2023年半年度报告全文及半年度报告摘要。为了更好地与广大投资 者进行交流，使投资者能够进一步了解公司的生产经营情况，公司拟 举办2023年半年度业绩说明会。具体安排如下： 特此公告。 上海海顺新型药用包装材料股份有限公司 董事会 公司定于2023年8月29日（星期二）15：00-16：30在全景网举行 2023年半年度业绩说明会。本次业绩说明会将会采用网络远程的方式 举行，投资者可登录"全景网投资者关系互动平台" （http://ir.p5w.net）参与本次业绩说明会。 届时，公司财务负责人倪海龙先生、董事会秘书杨高 ...

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2023-058 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 第五届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经与会监事认真审议，通过了以下议案： （一）审议通过《关于公司 2023 年半年度报告及年度报告摘要 的议案》； 经审议，监事会认为：董事会编制和审核公司《2023年半年度报 告》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、 准确、完整地反映了公司2023上半年经营的实际情况，不存在任何虚 假记载、误导性陈述或者重大遗漏。 一、 监事会会议召开情况 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届监事会第九次会议于2023年8月25日以现场和通讯的方式召开。 本次会议应出席监事3人，以现场方式出席监事3人，财务总监、董事 会秘书列席会议。会议的内容以及召集、召开的方式、程序均符合《公 司法》和《公司章程》的规定。 二、 监事会会议 ...

（一）审议通过《关于公司2023年半年度报告及半年度报告摘要 的议案》 经审议，与会董事认为：公司编制《2023 年半年度报告》及《2023 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定， 报告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚 | 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2023-057 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2023年8月15日以电话、微信、电子邮件等通讯方式发出召开第五 届董事会第九次会议的通知，会议于2023年8月25日以现场和通讯会 议方式召开，应出席董事7人，以现场方式出席董事7人，全体监事、 高级管理人员列席会议。本次董事会会议的召集、召开和表决程序符 合《公司法》等法律、法规及《公司章程》的有关规定，合法有 ...

上海海顺新型药用包装材料股份有限公司 2023 年第一季度报告 上海海顺新型药用包装材料股份有限公司 2023 年第一季度报告 | | | 上海海顺新型药用包装材料股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | （%） | | | 营业收入（元） | 260,137,982.34 | 231,871,055.84 | | 12.19% | | 归属于上市公司股 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,012,601,235.55, representing an increase of 18.18% compared to ¥856,857,795.71 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥102,461,491.00, a decrease of 2.09% from ¥104,645,765.20 in 2021[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥93,649,802.79, down 7.88% from ¥101,661,160.24 in 2021[20]. - The basic earnings per share for 2022 was ¥0.53, a decline of 17.19% compared to ¥0.64 in 2021[20]. - The total assets at the end of 2022 were ¥2,305,352,111.13, reflecting a growth of 1.82% from ¥2,264,050,337.46 at the end of 2021[20]. - The net assets attributable to shareholders increased by 5.74% to ¥1,596,620,328.83 at the end of 2022 from ¥1,509,959,144.83 at the end of 2021[20]. - The cash flow from operating activities for 2022 was ¥136,957,656.04, a slight decrease of 1.92% from ¥139,639,384.21 in 2021[20]. - The company achieved a revenue of ¥1,012,601,235.55 in 2022, representing an 18.18% increase year-over-year[48]. - The net profit attributable to the listed company was ¥102,461,491.00, a decrease of 2.09% compared to the previous year[48]. - The gross profit margin for new pharmaceutical packaging materials decreased by 2.38% to 28.75%, while the gross profit margin for hard packaging increased by 2.58% to 29.12%[58]. Dividend Distribution - The company reported a profit distribution plan to distribute a cash dividend of 0.5 CNY per 10 shares (including tax) based on a total of 193,531,505 shares[3]. - The company plans to distribute a cash dividend of RMB 0.5 per 10 shares, totaling RMB 9,676,575.25 (including tax) for the fiscal year 2022[163]. - The total number of shares for the dividend distribution is based on 193,531,505 shares, with a cash dividend amounting to 100% of the total profit distribution[163]. - The company's distributable profit for the period is RMB 518,276,767.53[163]. - No bonus shares or capital reserve transfers to increase share capital are proposed for this distribution[163]. Research and Development - R&D expenses increased by 35.32% during the reporting period, reflecting the company's commitment to innovation and product development[49]. - The company is focused on developing new products such as flame-retardant polypropylene films for lithium battery packaging and moisture-proof blister packaging for pharmaceuticals[72]. - The number of R&D personnel increased by 31.76% from 85 in 2021 to 112 in 2022, representing 13.74% of the total workforce[72]. - R&D investment amounted to ¥44,490,523.83 in 2022, up 35.36% from ¥32,877,686.18 in 2021, accounting for 4.39% of operating revenue[73]. - The company emphasizes technology R&D as a key driver for growth, with a strategic focus on enhancing core competitiveness through increased R&D personnel and investment[73]. Market and Industry Outlook - The pharmaceutical packaging industry in China is projected to grow, with a market size of approximately ¥135.86 billion in 2021, reflecting a year-on-year growth of 16%[32]. - The company aims to enhance its international competitiveness and stabilize supply chains by accelerating industrial upgrades and developing new products and technologies[33]. - Future outlook includes plans to expand market presence in the pharmaceutical packaging sector, targeting a 25% increase in market share over the next two years[94]. - The company is investing in R&D for new high-barrier coating materials, with an expected launch in Q3 2023[94]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[192]. Risks and Challenges - The company faces various risks including market competition, raw material price fluctuations, and potential declines in gross margin[3]. - The company has faced significant challenges due to rising raw material prices and a shortage of core equipment, leading to increased production costs[33]. - The company is exposed to raw material price volatility risks, particularly for aluminum and petroleum derivatives, and will manage inventory and supplier relationships to mitigate these risks[110]. - The company has faced risks from industry policy adjustments, with the National Medical Products Administration implementing stricter regulations on drug packaging materials since 2016, which could impact operations if not adapted to new requirements[111]. - The company is at risk of underutilizing new production capacity if market demand or competitive dynamics change significantly, despite thorough feasibility studies conducted for new projects[113]. Corporate Governance - The company maintains independence from its controlling shareholders, ensuring separate operations in assets, personnel, finance, and business[123]. - The company emphasizes information disclosure, adhering to legal requirements and ensuring timely and accurate information dissemination[120]. - The company has established specialized committees under the board, including a strategy and investment decision-making committee, to provide professional opinions[119]. - The company has implemented a robust internal management and control system to enhance governance levels[118]. - The company has complied with all relevant laws and regulations regarding corporate governance, with no significant discrepancies noted[122]. Employee and Management - The company has increased its employee count to 815, a significant growth compared to the previous year, supporting its operational capabilities[53]. - The total remuneration paid to the board of directors, supervisors, and senior management for 2022 amounted to 5.4679 million yuan[143]. - The company has implemented a performance-based salary system, adjusting employee compensation annually based on company performance and individual contributions[156]. - The company provided restricted stock incentives to outstanding employees to enhance team cohesion and core competitiveness[157]. - The company conducted training programs for new employees, marketing personnel, and management to improve skills and adapt to new management models[158]. Environmental Responsibility - The company has implemented a comprehensive environmental protection strategy, with all pollution control facilities operating normally and no administrative penalties received for environmental issues during the reporting period[178]. - The company emphasizes green development and has invested in pollution control technology, ensuring compliance with national and local environmental regulations[178]. - The company has implemented measures to reduce carbon emissions and has continuously invested in and upgraded environmental protection facilities to comply with national regulations[179]. - The company has developed energy usage plans tailored to each subsidiary's business characteristics to improve energy efficiency and reduce waste[181]. - The company emphasizes the importance of social responsibility, aiming for a balance between economic and social benefits, and promoting sustainable development[182].

公司定于2023年4月7日（星期五）15：00-17：00在全景网举行2022 年度业绩说明会。本次业绩说明会将会采用网络远程的方式举行，投 资者可登录"全景网投资者关系互动平台"（http://ir.p5w.net） 参与本次业绩说明会。 证券代码：300501 证券简称：海顺新材 公告编号：2023-026 上海海顺新型药用包装材料股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2023年3月31日在巨潮资讯网（http://www.cninfo.com.cn）披露 了2022年年度报告全文及年度报告摘要。为了更好地与广大投资者进 行交流，使投资者能够进一步了解公司的生产经营情况，公司拟举办 2022年度业绩说明会。具体安排如下： 届时，公司董事长兼总经理林武辉先生、财务负责人倪海龙先生、 独立董事王琳琳女士、董事会秘书杨高锋先生，保荐代表人姚奔先生 将出席本次业绩说明会。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩 说明会提前 ...

编号：2016-07-01 证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|----------------|---------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | ■ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | 西南证券 | 张汪强 | | 及人员姓名 | 西南证券 | 施跃 | | | 信诚基金 | 杨强 | | | 泰信基金 | 徐慕浩 | | | 建信基金 | 陈洁馨 | | | 财通资管 | 顾明豪 | | | 常春藤 | 冯先涛 | | | 天风证券 | 余方升 | | --- | --- | |----------------------------|------------| | | | | 华宝兴业基金 | 郎超 | ...